Intellia Shares Drop 3% After Positive Trial

Intellia Therapeutics shares fell 3% on Monday despite earlier rise after announcing positive Phase 3 HAELO trial results.
The trial of lonvo‑z (lonvoguran ziclumeran) reduced hereditary angioedema attacks by 87% versus placebo, with mean monthly attacks 0.26 vs 2.10.
Study enrolled 80 patients (52 treatment, 28 placebo); all treated patients remained free from long‑term prophylaxis as of Feb 10 data cutoff.
Intellia started a rolling BLA with FDA, aiming for U.S. launch in H1 2027 and will present data at June 2026 EAACI Congress.